Liquid biopsy for monitoring anaplastic lymphoma kinase inhibitors in non-small cell lung cancer: two cases compared

Three to seven percent of non-small cell lung cancer (NSCLC) patients show anaplastic lymphoma kinase (ALK)-translocation and could be treated with ALK-inhibitors. However, under crizotinib, a first-generation ALK-inhibitor, patients develop drug resistance after a median of 12 months. To overcome c...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Thorac Dis
Egile Nagusiak: Manicone, Mariangela, Scaini, Maria Chiara, Rodriquenz, Maria Grazia, Facchinetti, Antonella, Tartarone, Alfredo, Aieta, Michele, Zamarchi, Rita, Rossi, Elisabetta
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AME Publishing Company 2017
Gaiak:
Short Communication
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5676101/
https://ncbi.nlm.nih.gov/pubmed/29184678
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2017.08.151
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak